IGSF11 targeting antibody

IGSF11 targeting antibody is a **first-in-class monoclonal antibody** program directed against **immunoglobulin superfamily member 11**, also known as **VSIG3**, an immune checkpoint ligand implicated in tumor immune evasion. Preclinical literature and company disclosures indicate that blocking IGSF11 is intended to disrupt the **IGSF11-VISTA checkpoint axis**, thereby relieving immune suppression and enhancing antitumor immune responses, with particular interest in **PD-1 or PD-L1 resistant solid tumors**. The best-identified specific program matching this query is **IMT-18**, developed by **iOmx**, which has been described as a preclinical or in-development anti-IGSF11 antibody; however, public domain information remains limited and no marketed product name, dosing form, or confirmed clinical-stage regimen has been clearly established.

Other names

anti-IGSF11 antibodyanti-IGSF-11 antibodyanti-IGSF 11 antibodyIGSF11-targeting antibodyIGSF-11-targeting antibodyIGSF 11-targeting antibodyanti-VSIG3 antibodyanti-VSIG-3 antibodyanti-VSIG 3 antibody